Press Releases

09 Mar

Uncategorized

EastGate Biotech Announces Expansion and Restructuring of Joint Venture with its Partner in Pakistan

• March 9, 2022
• By admin
• 0 comments

Key products to be tested, registered and marketed include Insugin for diabetes application, alternative insulin for Alzheimer’s applic...

Continue reading

09 Mar

Uncategorized

EastGate Biotech Receives Regulatory Approval to Initiate a Phase III 90-day clinical trial on Insugin, its liquid insulin mouth rinse solution.

• March 9, 2022
• By admin
• 0 comments

The Marketing Application Approval in Pakistan will follow subject to completion of the Phase III clinical study that will include ...

Continue reading

09 Mar

Uncategorized

Eastgate Biotech Corp (OTC: ETBI) Management Interview

• March 9, 2022
• By admin
• 0 comments

Eastgate Biotech Corp (OTC: ETBI) Management Interview   Interview with COO Bill Abajian Eastgate’s new COO took time...

Continue reading

09 Mar

Uncategorized

EastGate Biotech Announces Appointment of Bill Abajian to Lead Licensing and Marketing Phase as Chief Operating Officer

• March 9, 2022
• By admin
• 0 comments

EastGate Biotech Announces Appointment of Bill Abajian to Lead Licensing and Marketing Phase as Chief Operating Officer WEST CALDWEL...

Continue reading

09 Mar

Uncategorized

EastGate Biotech Files Application to Initiate Phase III clinical trial for Insugin

• March 9, 2022
• By admin
• 0 comments

Approximately 200 patients will be included in the Phase III study in order to achieve regulatory approval in Pakistan     ...

Continue reading

09 Mar

Uncategorized

Bill Abajian of EastGate Biotech Corp. to speak at the 2019 M&A Forum for Pharma, Biotech and Med Device to be held between August 12 – 14, 2019 in Philadelphia

• March 9, 2022
• By admin
• 0 comments

Forum to focus on Innovative Partnership Opportunities for Product, Portfolio and Market Development     WEST CALDWELL, NJ...

Continue reading

09 Mar

Uncategorized

EastGate Biotech Announces Preparation to Initiate Phase III Clinical Trials on Insugin, its Liquid Insulin Mouth Rinse for Type 2 diabetes patients

• March 9, 2022
• By admin
• 0 comments

Multi-Center Phase III trial planned for 2019 WEST CALDWELL, NJ and TORONTO, ON /NEWMEDIAWIRE/ May 15, 2019/ Eastgate Biotech Co...

Continue reading

09 Mar

Uncategorized

EastGate Biotech Announces Positive Phase II Clinical Results of its Innovative Liquid Insulin Mouth Rinse Solution for Type 2 Diabetes

• March 9, 2022
• By admin
• 0 comments

Following a 3-month treatment, significant Hb1c Reduction was observed with administration of a single dose of Insugin two times a ...

Continue reading

09 Mar

Uncategorized

Eastgate BioTech Corp (OTCBB: ETBI) Interview with CEO Anna Gluskin

• March 9, 2022
• By admin
• 0 comments

https://wallstreetanalyzer.com/2019/04/09/eastgate-biotech-corp-otcbb-etbi-interview-with-ceo-anna-gluskin/

Continue reading

09 Mar

Uncategorized

Eastgate Biotech Signs Strategic Alliance Agreement with MJ Biopharm for Insulin API Supply

• March 9, 2022
• By admin
• 0 comments

Alliance with MJ Biopharm of Mumbai, India positions the company to further its plans for SEA countries for its liquid insulin mout...

Continue reading